Ladarixin sodium

Cat. No.: HY-19519A

CAS No.: 865625-56-5

Molecular Formula: $C_{11}H_{11}F_3NNaO_6S_2$

Molecular Weight: 397.32

Target: CXCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (251.69 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5169 mL	12.5843 mL	25.1686 mL
	5 mM	0.5034 mL	2.5169 mL	5.0337 mL
	10 mM	0.2517 mL	1.2584 mL	2.5169 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma[1].

IC_{50} & Target	CXCR1	CXCR2

In Vitro

Ladarixin inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 (IC_{50} at 0.7 nM)[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin

reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure[1].
Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice [1].
Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection[1].
Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (cigarette smoke-induced exacerbation of Influenza-A infection model)[1]
Dosage:	10 mg/kg
Administration:	P.o. once a day at days 2, 3 and 4 post-infection
Result:	Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group.

REFERENCES

[1]. Matheus Silverio Mattos, et al. CXCR1 and CXCR2 Inhibition by Ladarixin Improves Neutrophil-Dependent Airway Inflammation in Mice. Front Immunol. 2020 Oct 2;11:566953.

[2]. Daria Marley Kemp, et al. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget. 2017 Feb 28;8(9):14428-14442.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA